NCT07142954

Epidemiology and Biomarker Study in Alzheimer's Disease

A Longitudinal, Prospective Epidemiology Study in Alzheimer's Disease: Assessing Neurocognitive and Biomarker Changes and Health Outcomes in Individuals at Risk for Symptoms of Alzheimer's Disease (ANCHOR-AD)

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 3,400 (estimated)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 55 Years – 75 Years
• Healthy volunteers: Accepted

Summary

Study AACU determines rates of cognitive worsening in participants within elevated and not elevated plasma P-tau217 cohorts. Participation in AACU will last approximately 7 years.

Detailed description

Study AACU is a non-drug interventional study. The intervention is annual plasma P-tau217 testing. Enrollment is anticipated to be approximately 3400 participants.

Conditions

• Alzheimer Disease

Interventions

Type	Name	Description
OTHER	P-tau217 Test	A plasma test measuring phosphorylated tau at Position 217 (P-tau217).

Timeline

• Start date: 2025-08-25
• Primary completion: 2033-07-01
• Completion: 2033-07-01
• First posted: 2025-08-27
• Last updated: 2026-02-10

Locations

3 sites across 2 countries: United States, Japan